Latest Content

Two promising psychiatrists have tragically passed away.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

"Without a father to guide me north, your poems were a compass pointing toward a world where doctors can be poets..."

FDA committee discusses potential and risks of AI-enabled digital mental health devices.

A recent study links lower income to higher dementia risk factors, highlighting the need for targeted interventions in vulnerable populations.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.

Veterans face significant PTSD challenges, with tailored treatments and ongoing research essential for improving their mental health outcomes.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.